Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

被引:419
|
作者
Kasahara, A
Hayashi, N
Mochizuki, K
Takayanagi, M
Yoshioka, K
Kakumu, S
Iijima, A
Urushihara, A
Kiyosawa, K
Okuda, M
Hino, K
Okita, K
机构
[1] Osaka Univ, Sch Med, Dept Med 1, Suita, Osaka 5650871, Japan
[2] Nagoya Univ, Sch Med, Dept Med 3, Nagoya, Aichi 466, Japan
[3] Shinshu Univ, Sch Med, Dept Med 2, Matsumoto, Nagano 390, Japan
[4] Yamaguchi Univ, Sch Med, Dept Med 1, Ube, Yamaguchi 755, Japan
关键词
D O I
10.1002/hep.510270529
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To elucidate the risk factors for liver carcinogenesis and to examine the incidence of hepatocellular carcinoma (HCC) after interferon therapy, 1,022 chronic hepatitis C patients treated with interferon were followed by ultrasonography for 13 to 97 months (median 36 months). Sustained response with prolonged alanine aminotransferase normalization was found in 313 patients, transient response with alanine aminotransferase relapse after therapy in 304, and no response in 405, Forty-six developed HCC, of whom 5 were sustained responders, 9 were transient responders, and 32 were nonresponders. The cumulative incidence of HCC in transient responders was almost equal to that in sustained responders, and it was significantly higher in nonresponders than in sustained and transient responders (P = .0009), The seventh-year cumulative incidence rates of HCC in sustained responders, transient responders, and nonresponders mere estimated to be 4.3%, 4.7%, and 26.1%, respectively. However, there was no significant difference in the cumulative incidence of HCC between patients with HCV subtype 1 and 2 (P = .14). Cox regression analysis showed that the risk of HCC development was not elevated in transient responders compared with sustained responders, but that the risk was 7.90-fold higher in nonresponders than in sustained responders (P = .008), Patients greater than or equal to 55 years of age had a significantly higher risk ratio (4.65) than did those under 55 years of age (P = .006). The risk of HCC development in men was 4.35 times higher than the risk in women (P = .02). However, the degree of fibrosis was not a significant risk factor for the development of HCC (risk ratio, 3.16; P = .052). These results suggest that patients in the high-risk group of HCC after interferon therapy were those who showed no response, those who were older, and those who were male, and that such patients should be carefully followed using ultrasonography.
引用
收藏
页码:1394 / 1402
页数:9
相关论文
共 50 条
  • [21] Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C.
    Kasahara, A
    Hayashi, N
    Sasaki, Y
    Kakumu, S
    Kiyosawa, K
    Okita, K
    HEPATOLOGY, 2000, 32 (04) : 361A - 361A
  • [22] The Incidence and Risk Factors for the Development of Hepatocellular Carcinoma after Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
    Dohmen, Kazufumi
    Kawano, Akira
    Takahashi, Kazuhiro
    Shigematsu, Hirohisa
    Tanaka, Hirofumi
    Haruno, Masatora
    Yanagita, Kimihoko
    Ichiki, Yasunori
    Mori, Tetsu
    Hayashida, Kazuhiro
    Shimoda, Shinji
    Ishibashi, Hiromi
    Nomura, Hideyuki
    HEPATO-GASTROENTEROLOGY, 2013, 60 (128) : 2034 - 2038
  • [23] Immunodulator Effects of Interferon Therapy on Incidence of Cirrhosis and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
    Kutala, Blaise
    Boyer, Nathalie
    Marchand, Corinne Castelnau
    Guigui, Nathalie Giuily
    Sitruk, Veronique
    Asselah, Tarik
    Marcellin, Patrick
    HEPATOLOGY, 2018, 68 : 407A - 408A
  • [24] Significant factors for incidence of hepatocellular carcinoma after sustained virological response to antiviral treatment for chronic hepatitis C
    Furusyo, N.
    Murata, M.
    Ogawa, E.
    Nomura, H.
    Hayashi, J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 : S129 - S130
  • [25] Lifestyle risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients
    Matsuura, Tomoka
    Ohfuji, Satoko
    Enomoto, Masaru
    Tamori, Akihiro
    Kubo, Shoji
    Kioka, Kiyohide
    Fukushima, Wakaba
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2021, 50
  • [26] Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
    Leal, Cassia
    Strogoff-de-Matos, Jorge
    Theodoro, Carmem
    Teixeira, Rosangela
    Perez, Renata
    Guarana, Thais
    Pinto, Paulo de Tarso
    Guimaraes, Tatiana
    Artimos, Solange
    VIRUSES-BASEL, 2023, 15 (01):
  • [27] INCIDENCE OF HEPATOCELLULAR CARCINOMA AFTER ACHIEVING SUSTAINED VIROLOGICAL RESPONSE TO INTERFERON THERAPY FOR CHRONIC HEPATITIS C
    Watanabe, Hisayoshi
    Saito, Takafumi
    Ishii, Rika
    Sato, Chikako
    Haga, Hiroaki
    Sanja, Mai
    Okumoto, Kazuo
    Nishise, Yuko
    Ito, Junitsu
    Saito, Koji
    Kawata, Sumio
    HEPATOLOGY, 2010, 52 (04) : 1164A - 1164A
  • [28] Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States
    Ming Yang
    Neehar D. Parikh
    Huixin Liu
    Elizabeth Wu
    Huiying Rao
    Bo Feng
    Andy Lin
    Lai Wei
    Anna S. Lok
    Scientific Reports, 10
  • [29] Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States
    Yang, Ming
    Parikh, Neehar D.
    Liu, Huixin
    Wu, Elizabeth
    Rao, Huiying
    Feng, Bo
    Lin, Andy
    Wei, Lai
    Lok, Anna S.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [30] Preventive effect of interferon treatment on the incidence of hepatocellular carcinoma in chronic hepatitis C with advanced histological stages
    Imai, Y
    Kawata, S
    Tamura, S
    Yabuuchi, I
    Noda, S
    Inada, M
    Maeda, Y
    Shirai, Y
    Fukuzaki, T
    Kaji, I
    Ishikawa, H
    Matsuda, Y
    Matsuzawa, Y
    HEPATOLOGY, 1997, 26 (04) : 1141 - 1141